Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q2 2017 Earnings Presentation

28 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 2, 2017

  1. Slide 1: Second Quarter 2017 Corporate Update and Financial Results

    August 2, 2017 Second Quarter 2017 Corporate Update and Financial Results 1

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2

  3. Slide 3: Agenda

    Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to dif fer

  5. Slide 5: Non-GAAP Metrics

    Non - GAAP Metrics This presentation contains four financial metrics (Adjusted Net Income, EBITDA, Adjusted EBITDA and Free Cash Flow) that are con sidered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metr ics sh

  6. Slide 6: Q2 2017

    Q2 2017 Corporate Update Peter Greenleaf, Chairman and CEO 6

  7. Slide 7: Vtesse Inc. Acquisition

    Vtesse Inc. Acquisition • Sucampo closed acquisition of Vtesse and progressed with its successful integration • VTS - 270 for the treatment of NPC - 1 in global pivotal registration program • Ultra - rare disorder with devastating and ultimately fatal outcome • Fully enrolled, results in 2018 • Secu

  8. Slide 8: Strong Q2 2017 U.S. AMITIZA Performance

    Strong Q2 2017 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes • Q2 grew 9% YoY to $110.7M • Driven by increased volume and price • Royalty revenue grew 10% YoY to $20.6M • U.S. AMITIZA product sales to Takeda of $13.5M • Total U.S. revenue of $34.1M • AMITIZA

  9. Slide 9: Strong Japan AMITIZA Performance

    Strong Japan AMITIZA Performance • Sucampo Q2 revenue: $18.6M, growth of 27% YoY • Growth driven by volume • Increased 24% YoY • Patient demand for AMITIZA remains strong in an increasingly competitive market • Strong commercial execution by Mylan 9

  10. Slide 10: Additional Operational Highlights

    Additional Operational Highlights • CPP collaboration in FAP: futility analysis outcome is recommendation by Independent Data Monitoring Committee that ongoing Phase 3 trial not discontinue • Commenced building organization in preparation for NDA approvals/launches 10

  11. Slide 11: 2017 Guidance Maintained

    2017 Guidance Maintained • Total revenue: $220 million to $230 million • Adjusted net income: $56 million to $66 million • Adjusted EBITDA: $109 million to $119 million • Adjusted EPS: $1.00 to $1.10 • Free cash flow of $86 million to $96 million 11

  12. Slide 12: Pipeline Update

    Pipeline Update Peter Kiener, D. Phil, CSO 12 12

  13. Slide 13: VTS-270 for Treatment of NPC-1

    VTS - 270 for Treatment of NPC - 1 13 Until regulatory decision • IT injections every 2 weeks • Trial fully enrolled • Part B is key phase for NDA submission; completes end of March 2018 • Pivotal data expected in mid - 2018 • Potential regulatory approval in U.S. and EU in 1H19 12 months for any si

  14. Slide 14: VTS-270, continued

    VTS - 270, continued • Granted a patent for VTS - 270 that protects the differentiated composition of VTS - 270 and strengthens our intellectual property position for the program • Progressing efforts in additional product innovation 14

  15. Slide 15: CPP-1X/Sulindac for Treatment of FAP

    CPP - 1X/Sulindac for Treatment of FAP • CPP - 1X/sulindac is being developed to treat Familial Adenomatous Polyposis, a predominately genetic disease • If left untreated, FAP eventually develops into colon cancer in 100% of patients • Orphan disease in U.S. and Europe • Ongoing Phase 3 study is a 1

  16. Slide 16: Product Pipeline

    Product Pipeline 16 Sucampo Program Option Program Target First Indication Development Stage (s)NDA/MAA Filing Approval AMITIZA CIC2 Pediatric functional constipation (6-17 yrs.) P3 2017 2018 Lubiprostone Sprinkle Formulation CIC2 Pediatric functiontional constipation 6 mos-5 yrs (1); adult CIC (2)

  17. Slide 17: Financial Update

    Financial Update Peter Pfreundschuh, CFO 17 17

  18. Slide 18: Continued Financial and Operational Performance

    Continued Financial and Operational Performance EARNINGS • GAAP net loss in Q2 driven by one - time IP R&D charge of $186.6M due to Vtesse acquisition Summary of Results Q2 - 17 Q2 - 16 Net Loss GAAP ($181.2M) (0.832 M) EPS GAAP – diluted ($3.92) ($0.02) EBITDA ($169.3M) 17.9M Adjusted Net Income $1

  19. Slide 19: Q2 Adjusted Net Income

    Q2 Adjusted Net Income 19 16.5 5.6 5.4 3.1 1.8 1.5 10.3 0.0 5.0 10.0 15.0 20.0 25.0 Q2 2016 Gross margin Interest expense R&D exp excl. Vtesse Vtesse related expenses Other Q2 2017

  20. Slide 20: Q2 Adjusted EBITDA

    Q2 Adjusted EBITDA 20 27.4 5.6 5.4 1.8 0.8 25.0 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 Q2 2016 Gross margin R&D exp excl. Vtesse Vtesse related expenses Other Q2 2017

  21. Slide 21: Q2 Revenue

    Q2 Revenue 21 59.9 4.0 1.9 1.8 0.2 52.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 Q2 2016 Amitiza Japan product sales Product sales Amitiza US royalty Other Q2 2017

  22. Slide 22: Q2 Adjusted Net Income

    Q2 Adjusted Net Income 22 16.5 5.6 5.4 3.1 1.8 1.5 10.3 0.0 5.0 10.0 15.0 20.0 25.0 Q2 2016 Gross margin Interest expense R&D exp excl. Vtesse Vtesse related expenses Other Q2 2017

  23. Slide 23: Key Balance Sheet Items

    Key Balance Sheet Items 23 Balance Sheet End 6/30/17 Change End 12/31/16 Cash, Cash Equivalents and Restricted Cash $84.9M ($113.6M) $198.5M Notes Payable $291.5M $1.0M $290.5M Net Debt $206.6M $114.6M $92.0M

  24. Slide 24: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO 24 24

  25. Slide 25: 2017 Areas of Focus

    2017 Areas of Focus 1. Deliver strong financial performance 2. Accelerate priority clinical programs 3. Evaluate and execute on additional opportunities for growth 25

  26. Slide 26: Q&A Session

    Q&A Session e ? SUCAMPO

  27. Slide 27: Reconciliation of GAAP Net Loss to Non-GAAP Net Income

    Reconciliation of GAAP Net Loss to Non - GAAP Net Income RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended June 30, 2017 June 30, 2016 Adjusted Net Income: GAAP net loss (181,167) (832) Amortization intangibles 6,7

  28. Slide 28: Reconciliation of Income from Operations to Adjusted EBITDA

    Reconciliation of Income from Operations to Adjusted EBITDA 28 RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (in thousands, except per share amounts) Three Months Ended Three Months Ended June 30, 2017 June 30, 2016 GAAP net loss (181,167) (832) Adjustments: Taxes 1,940 (51) Interest expense

Sucampo Pharmaceuticals — Q2 2017 Earnings Presentation on 6ix